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Acromegaly is an uncommon pituitary disease, character- 
ized by progressive bone and organ overgrowth, and 
frequently accompanied by dysfunctional cardiovascular, 
cerebrovascular and respiratory systems, which con- 
tribute to the premature deaths observed in this condi- 
tionlA. In addition, evidence is growing to suggest that 
acromegaly might predispose to an increased risk of 
benign and malignant neoplasms, thus influencing the 
final outcome of the disease1-5. Such neoplastic lesions 
have been reported predominantly in the gastrointestinal 
tract, but sites such as the breast, thyroid, skin and 
lymphohaematological system have also been found to 
be involved5-14. 
The exact mechanism of neoplastic events in 
acromegaly has not been completely clarified. In z&o 
studies indicate an autocrine-paracrine role for growth 
hormone (GI-I) and insulin-like growth factor I (IGF-I) in 
the proliferation of cells. Such factors may stimulate the 
proliferation and transformation of cells by means of spe- 
cific membrane, cytoplasmic and nuclear receptors15-17, 
and may induce proto-oncogene transcription, thus 
demonstrating probable tumorigenic activity. In z&o, GH 
therapy has been associated with an increased risk of 
neoplasms of the lymphopoietic system, adrenal gland, 
ovaries and breast, both in animal models and in young 
humans who have received GH therapylR1g, although 
such findings have not been confirmed by more recent 
reports20-22. 
A role for IGF-I in cancer development has also been 
suggested by the finding of higher IGF-I levels in patients 
suffering from prostate or breast cancer, although a pre- 
cise explanation of the source of this IGF-I production is 
still awaited23*24. On the basis of these observations and 
the claim that IGF-I is a positive predictor of prostate 
cancer, the role of IGF-I in prostate development is cur- 
rently under thorough investigation. 
In a recent study25, we assessed the effect of GH and 
IGF-I levels on prostate pathophysiology in 46 patients 
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with acromegaly (30 with active disease, 10 cured and 
6 with GH deficiency [GHD]) and 30 age-matched male 
controls (free from previous or concomitant prostate dis- 
orders), who were undergoing pituitary, androgen and 
prostate hormonal assessments and transrectal ultra- 
sonography (TRUS). In patients with active disease, GH, 
IGF-I and IGF-binding protein-3 (IGFBP-3) levels were 
increased, and testosterone and dihydrotestosterone 
levels were reduced, compared with controls. Hypo- 
gonadism was present in 28 of the 46 patients with 
acromegaly (60.8%). The anteroposterior and transverse 
prostate diameters and the prostate transitional zone 
volume were increased in the patients with acromegaly 
compared with the controls. Prostate volume (PV) 
was significantly higher in untreated patients with 
acromegaly than in controls, cured and GH-deficient 
patients. In the patients with active disease, PV sign& 
cantly correlated with disease duration (I = 0.606, 
P < 0.0001) and age (I = 0.496, P < O.OOOl), whereas in 
controls it correlated with age (r = 0.476, P < 0.01) and 
IGF-I levels (r= -0.448, P< 0.05). Benign prostate hyper- 
plasia (BPH; PV 130 ml) was found in 58% of the patients 
and 26.6% of the controls. When grouped by age (< 40 
years, 40-60 years and > 60 years), PV was higher in 
elderly patients than in younger ones and controls. The 
prevalence of structural abnormalities, including calcifi- 
cations, nodules, cysts and vesicle inflammation, was 
significantly higher in patients compared with controls 
(78.2 versus 23.3%; x2 = 5.856, P < 0.05). No clinical, 
TRUS or cytological evidence of prostate cancer was 
detected in patients with acromegaly or controls. An 
increased prevalence of BPH and micro-/macro-calcifica- 
tions was also found in young patients with acromegaly, 
despite the fact that all patients had secondary hypo- 
gonadism, as diagnosed by low testosterone 1eveW. After 
1 year of treatment with octreotide (0.3-0.6mg/day), 
normalization of circulating GH and IGF-I levels was 
achieved in seven of 10 patients. In these seven patients, 
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TRUS significantly reduced the anteroposterior, trans- 
verse and craniocaudal diameters of the prostate. As a 
consequence, a significant decrease in PV was recorded. 
PV increased in two of the three patients who did not 
achieve normalization of GH and IGF-I after octreotide 
treatmentz6. 
In conclusion, although a number of reports suggest 
that longer exposure to elevated GH/IGF-I levels is asso- 
ciated with an increased risk of cancer, most epidemio- 
logical studies do not focus on strict biochemical criteria 
in evaluating this risk, and it is therefore not possible to 
exclude a direct cause-effect relationship as a result of 
the persistence of active disease. In particular, although a 
chronic excess of GH and IGF-I caused prostate over- 
growth and other structural abnormalities, no case of 
prostate cancer was observed in our series. In fact, there 
appeared to be an overall reduction in the incidence of 
cancer events in those patients with acromegaly who 
achieved long-term biochemical remission with surgery, 
radiotherapy or pharmacotherapy, although long-term 
prospective studies are needed to confirm this finding. 
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